title: Experience with TachoSil in obstetric and gynecologic surgery.
abstract: OBJECTIVE
  To evaluate the feasibility and effectiveness of using TachoSil during obstetric and gynecologic surgery.
  
  
  METHODS
  The retrospective cohort study, conducted at a French university hospital, included women who experienced perioperative bleeding requiring the use of TachoSil during 2007-2009. The following information was collected: patient age, indication for the use of TachoSil, need for a blood transfusion, type of surgery performed, postoperative course, and traceability of TachoSil.
  
  
  RESULTS
  TachoSil was used in 84 women. The main indications for the surgical interventions requiring TachoSil were ovarian malignancy (n=18), fibroma (n=17), breast cancer (n=11), and endometrial cancer (n=10). In 16 women, TachoSil was applied to the uterine serosa, particularly after cesarean delivery or polymyomectomy; in 7 women, it was applied to the major vascular axis. Red cell packs were infused in 24 women during surgery (average 3 packs per woman). Three women required repeat surgery. The use of TachoSil was not recorded in the operative reports of 43 (51%) women.
  
  
  CONCLUSIONS
  The present findings confirm that the use of TachoSil in gynecologic and obstetric surgeries is effective and well tolerated. Measures to improve the traceability of TachoSil use are recommended.
authors: Department of Obstetrics and Gynecology, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, CancerEst, Université Pierre et Marie Curie (UPMC), Paris, France.
authors: Pietro
authors: P
authors: Santulli
authors: Louis
authors: L
authors: Marcellin
authors: Cyril
authors: C
authors: Touboul
authors: Marcos
authors: M
authors: Ballester
authors: Emile
authors: E
authors: Darai
authors: Roman
authors: R
authors: Rouzier
mesh_terms: D016063:Blood Loss, Surgical; D001803:Blood Transfusion; D015331:Cohort Studies; D004338:Drug Combinations; D005240:Feasibility Studies; D005260:Female; D005340:Fibrinogen / Q000009:adverse effects / Q000627:therapeutic use*; D005602:France; D013509:Gynecologic Surgical Procedures / Q000009:adverse effects / Q000379:methods*; D006785:Hospitals, University; D006801:Humans; D008875:Middle Aged; D013513:Obstetric Surgical Procedures / Q000009:adverse effects / Q000379:methods*; D011247:Pregnancy; D012189:Retrospective Studies; D015503:Surgical Sponges; D013917:Thrombin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C518955:TachoSil; D005340:Fibrinogen; D013917:Thrombin